Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.

ABSTRACT: Urothelial carcinoma (UC) is a frequently diagnosed tumor and an important cause of cancer deaths worldwide. Until a few years ago, despite the unquestioned role of platinum-based chemotherapy, therapeutic choices beyond the first line were limited and related to unsatisfactory outcomes. Metastatic UC has always been associated with a poor prognosis, with overall survival only slightly above a year. In the recent past, huge progress has been made in our understanding of the molecular and genomic disease characteristics, to enable stratification of patients in terms of prognosis and treatment responses. Unfortunately, we still do not have the perfect combination of clinical biomarkers to tailor the optimal treatment for each patient, despite making several efforts in this direction. The the

SUBMITTER: Tassinari E 

PROVIDER: S-EPMC9205436 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature